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Abstract
Dextromethorphan is an antitussive with a high margin of safety that has been hypothesized to display rapid-acting
antidepressant activity based on pharmacodynamic similarities to the N-methyl-D-aspartate (NMDA) receptor antagonist
ketamine. In addition to binding to NMDA receptors, dextromethorphan binds to sigma-1 (s1) receptors, which are believed
to be protein targets for a potential new class of antidepressant medications. The purpose of this study was to determine
whether dextromethorphan elicits antidepressant-like effects and the involvement of s1 receptors in mediating its
antidepressant-like actions. The antidepressant-like effects of dextromethorphan were assessed in male, Swiss Webster mice
using the forced swim test. Next, s1 receptor antagonists (BD1063 and BD1047) were evaluated in conjunction with
dextromethorphan to determine the involvement of s receptors in its antidepressant-like effects. Quinidine, a cytochrome
P450 (CYP) 2D6 inhibitor, was also evaluated in conjunction with dextromethorphan to increase the bioavailability of
dextromethorphan and reduce exposure to additional metabolites. Finally, saturation binding assays were performed to
assess the manner in which dextromethorphan interacts at the s1 receptor. Our results revealed dextromethorphan displays
antidepressant-like effects in the forced swim test that can be attenuated by pretreatment with s1 receptor antagonists,
with BD1063 causing a shift to the right in the dextromethorphan dose response curve. Concomitant administration of
quinidine potentiated the antidepressant-like effects of dextromethorphan. Saturation binding assays revealed that a Ki
concentration of dextromethorphan reduces both the Kd and the Bmax of [
3H](+)-pentazocine binding to s1 receptors. Taken
together, these data suggest that dextromethorphan exerts some of its antidepressant actions through s1 receptors.
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Introduction
Depression affects up to one fifth of the world population, stands
as the second leading cause of disability worldwide, and imposes a
substantial economic burden [1,2]. In addition, the available
pharmaceutical agents for treating depression are not effective in
approximately a third of patients [3] and have a delayed clinical
efficacy of several weeks to months [4]. Consequently, there is still
a great need for faster acting and more effective treatments for
depression.
Recently, a hypothesis was offered that dextromethorphan may
have fast-acting antidepressant activity based on pharmacody-
namic similarities to the N-methyl-D-aspartate (NMDA) antago-
nist ketamine [5], a drug repeatedly shown in human populations
to display rapid antidepressant effects but whose use is severely
limited by the need for intravenous administration and the
presence of notable adverse effects (e.g., hallucinations and
dissociations) [6,7,8]. Similar to ketamine, dextromethorphan
binds to NMDA receptors and can modulate glutamatergic
signaling [5]. Dextromethorphan also has higher affinity than
ketamine for serotonin transporters (SERT) [9] and several other
protein targets, including sigma-1 (s1) receptors [5,9] which have
been proposed as therapeutic targets for antidepressant drugs [10].
Unlike ketamine, however, dextromethorphan has a high margin
of safety; it has been used as a nonprescription antitussive over the
past 40 years and thus may serve as a safer alternative to ketamine.
In addition, it readily undergoes first-pass metabolism by
cytochrome P450 (CYP) 2D6 to its major active metabolite
dextrorphan [11]. Dextromethorphan in combination with
quinidine, which raises the plasma concentration and bioavail-
ability of dextromethorphan through the inhibition of CYP2D6
metabolism [12], is approved by the U.S. Food and Drug
Administration (FDA) and European Medicines Agency (EMA) for
the treatment of pseudobulbar affect and is thought to produce
part of its therapeutic effects through s1 receptors [13].
s1 Receptors are highly conserved 223 amino acid proteins
expressed on the mitochondrial-associated endoplasmic reticulum
membrane (MAM) and can translocate between different cellular
compartments in response to ligand binding [14]. In addition, s1
receptors appear to operate primarily via protein-protein interac-
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tions to modulate the activity of various ion channels and signaling
molecules, including inositol triphosphates, protein kinases, and
calcium [14,15].
Previous reports implicate s1 receptors as protein targets for
existing and novel antidepressant drugs [10]. Currently marketed
antidepressant drugs, such as tricyclic antidepressants, monoamine
oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs),
and newer generations of antidepressant drugs, bind to these
receptors [10]. Earlier studies also demonstrate that s1 receptor
agonists can modulate the activities of neurotransmitter systems,
signaling pathways and brain regions implicated in the patho-
physiology of depression [10] and that s1 receptor knockout mice
exhibit a depressive-like phenotype [16].
The potential clinical relevance of these observations is further
supported by reports that s1 receptor agonists produce antide-
pressant effects in experimental animals and humans
[17,18,19,20,21,22]. Notably, the s1 receptor agonist igmesine
hydrochloride proved to be as effective an antidepressant as the
well-established SSRI fluoxetine in some clinical trials, though not
in all cases [10,22]. Compared to existing medications, s1 receptor
agonists may facilitate a more rapid onset of antidepressant
efficacy [23]. Consistent with this, s1 receptor agonists such as (+)-
pentazocine and SA 4503 can enhance serotonergic neuronal
firing in the dorsal raphe nucleus after only two days of treatment,
compared to the two weeks of treatment that is typically required
of conventional antidepressant drugs [24,25].
In the studies herein, we test the hypothesis that dextromethor-
phan can exert antidepressant-like actions at least in part through
s1 receptors. This activity may convey additional therapeutic
advantages over ketamine under clinically relevant conditions
since compared to ketamine which has micromolar affinity for s1
receptors [26], dextromethorphan exhibits nanomolar binding
affinity for these receptors [9,27,28]. First, the ability of
dextromethorphan to cause antidepressant-like effects was exam-
ined in the forced swim test. The forced swim test is the most
validated behavioral assay for predicting antidepressant efficacy
[3,29,30] and thus provides a rational format for the initial
evaluation of the antidepressant potential of dextromethorphan. In
addition, the effect of dextromethorphan on locomotor activity
was measured to determine whether stimulant effects could
account for its apparent antidepressant-like actions. The antide-
pressant drugs imipramine and fluoxetine were used as reference
ligands for these behavioral tests. Second, to evaluate the potential
involvement of s1 receptors in the in vivo antidepressant-like
actions of dextromethorphan, pharmacological antagonists target-
ing s1 receptors were examined for their ability to prevent the
antidepressant-like effects of dextromethorphan. Third, since
dextromethorphan undergoes extensive first-pass metabolism by
CYP2D6 to its major active metabolite dextrorphan [11], the
CYP2D6 inhibitor quinidine was administered concomitantly with
dextromethorphan to raise the plasma concentration and
bioavailability of dextromethorphan [12] and determine whether
the metabolism of dextromethorphan affects its antidepressant
efficacy. Finally, to define the manner in which dextromethorphan
binds to s1 receptors (competitive and/or non-competitive),
saturation binding studies were conducted.
Materials and Methods
Animals
Male, Swiss Webster mice (24–28 g; Harlan, Frederick, MD)
were housed with food and water ad libitum, with a 12:12 h light–
dark cycle. Animals were housed in groups of five for at least one
week prior to initiation of experiments. All procedures were
conducted in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee at West Virginia
University (Morgantown, WV), and all efforts were made to
minimize suffering.
Drugs and Chemicals
Dextromethorphan hydrobromide and quinidine sulfate were
provided by Avanir Pharmaceuticals, Inc. (Aliso Viejo, CA; for the
behavioral studies) or purchased from Sigma-Aldrich (St. Louis,
MO; for the binding assays). Imipramine hydrochloride was
purchased from Sigma-Aldrich (St. Louis, MO). Fluoxetine
hydrochloride, BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methyl-
piperazine dihydrochloride), and BD1047 (N-[2-(3,4-dichlorophe-
nyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobro-
mide) were obtained from Tocris (Ellisville, MO). [3H](+)-
Pentazocine (34.8 Ci/mmol) was procured from Perkin Elmer
(Hopkington, MA). All other chemicals and reagents were
purchased from standard commercial suppliers (Sigma-Aldrich,
St. Louis, MO).
Drug Treatments
Mice (N = 5–15/group) received intraperitoneal (i.p.) injections
with the following treatments: (1) Saline; (2) Imipramine (10–
20 mg/kg); (3) Fluoxetine (10–30 mg/kg); (4) Dextromethorphan
(1–30 mg/kg); (5) BD1063 (3–30 mg/kg); (6) BD1047 (10–30 mg/
kg); (7) BD1063 (10 mg/kg) + Imipramine (20 mg/kg); (8) BD1063
(10 mg/kg) + Dextromethorphan (10–50 mg/kg); (9) BD1047 (10–
20 mg/kg) + Dextromethorphan (30 mg/kg); (10) Quinidine
(30 mg/kg) + Saline; and (11) Quinidine (30 mg/kg) + Dextro-
methorphan (3–30 mg/kg). Treatment with quinidine was admin-
istered concurrently with saline or dextromethorphan. Treatment
with a s1 receptor antagonist (BD1063 or BD1047) was
administered 15 min prior to the second drug (imipramine or
dextromethorphan).
Locomotor Activity
Locomotor activity was measured utilizing an automated
activity monitoring system (San Diego Instruments, San Diego,
CA). Prior to locomotor activity measurements, animals were
acclimated to the testing facility for at least 30 min and habituated
to the testing chambers for an additional 30 min. Each testing
chamber consisted of a Plexiglas housing and a 16616 photobeam
array to detect lateral (ambulatory and fine) movements, with a
separate 16 photobeam array to detect rearing activity. Subse-
quent to the acclimation period, animals were treated and placed
back in their respective chambers. Ambulatory, fine and rearing
movements were quantified and summated as a measure of total
locomotor activity for the next 30 min.
Forced Swim Test
Immediately after the locomotor measurements, animals were
placed in individual cylinders of water (10 cm deep) for a total of
6 min for the forced swim test. The initial 2 min was an
acclimation period and not scored. During the remaining 4 min,
immobility time was quantified using ANY-Maze Version 4.63
video tracking software (Stoelting Co., Wood Dale, IL). Immobil-
ity was defined as no activity other than that required to maintain
the animal’s head above the surface of the water. ANY-Maze
software settings were as follows: accustomization period = 120 s,
test duration = 240 s, minimum immobility time = 2000 ms (2 s),
and immobility sensitivity = 75%.
Dextromethorphan and Antidepressant-like Effects
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Saturation Binding Assays
To determine Kd and Bmax by saturation binding, assays were
performed in the absence (control) and presence of dextrome-
thorphan (400 nM) using methods previously published in detail
[31]. The concentration of dextromethorphan used in these assays
was based on the reported Ki of the drug for s1 receptors [27].
Briefly, 15 concentrations of [3H](+)-pentazocine (0.1–100 nM)
were used to label s1 receptors in P2 rat brain homogenates (400–
500 mg/sample). Non-specific binding was determined in the
presence of 10 mM haloperidol. Incubations occurred for 120 min
at 25uC and membranes were washed 2–3 times using ice cold
10 mM Tris HCl, pH 8.0.
Data Analysis
Data from all experiments were analyzed using GraphPad
Prism 5.0 (San Diego, CA). The behavioral data were analyzed by
one-way analysis of variance (ANOVA) followed when applicable
by post-hoc Dunnett’s or Tukey’s multiple comparison tests. The
correlation between locomotor activity and immobility time was
analyzed by Pearson’s r correlation test. The Kd and Bmax were
determined using nonlinear regression and analyzed by unpaired
t-tests. For in vivo data, outliers (data points that were at least two
standard deviations away from the mean) were excluded from
analyses. Data are represented as mean 6 S.E.M. P,0.05 was
considered statistically significant for all data analyzed.
Results
Conventional Antidepressants Dose Response
The tricyclic antidepressant imipramine served as a positive
control and significantly altered immobility time in the forced
swim test (Figure 1A; F[2,32] = 10.24, P,0.05). Post-hoc Dunnett’s
test showed that imipramine at 20 mg/kg significantly decreased
immobility time when compared to saline (q = 4.52, P,0.001).
Imipramine did not alter locomotor activity, even at doses that
produced antidepressant-like effects (Figure 1B; F[2,30] = 0.23,
n.s.).
Consistent with earlier reports that the forced swim test does not
reliably detect the effects of SSRIs [37], the SSRI fluoxetine did
not significantly reduce immobility time in the forced swim test
under the conditions used by our laboratory (F[2,32] = 1.97, n.s.).
Fluoxetine also did not alter locomotor activity (F[2,30] = 2.36,
n.s.).
Dextromethorphan Dose Response
Dextromethorphan significantly reduced immobility time
(Figure 1C; F[4,50] = 6.16, P,0.001), with a post-hoc Dunnett’s
test revealing that 30 mg/kg differed significantly from saline
(q = 4.70, P,0.05). Dextromethorphan also produced significant
effects on locomotor activity (Figure 1D; F[4,48] = 4.27, P,0.05),
with post-hoc Dunnett’s tests confirming that the following doses of
dextromethorphan elicited effects that differed significantly from
the saline control: 1 mg/kg (q = 2.63, P,0.05) and 30 mg/kg
(q = 3.81, P,0.01). Since dextromethorphan showed significant
stimulant effects, a correlation analysis between locomotor activity
and immobility time was carried out to determine whether
stimulant effects could account for its apparent antidepressant-like
actions. The Pearson’s r correlation test revealed that there was no
correlation between the dextromethorphan-induced increase in
locomotor activity and decrease in immobility time (Figure 1E;
r = 20.02, n.s.)
Sigma-1 Receptor Antagonists Dose Response
When tested alone, the s1 receptor antagonist BD1063
displayed a significant effect on immobility time (F[3,36] = 4.11,
P,0.05). Post-hoc Dunnett’s tests showed that BD1063 significantly
reduced immobility time at 30 mg/kg (q = 3.41, P,0.01), but not
at 10 mg/kg (q = 1.82, n.s.). Consequently, all antagonist testing in
the forced swim test was performed with the 10 mg/kg dose of
BD1063 which did not have effects on its own. Alone, BD1063
also produced significant changes in locomotor activity
(F[3,34] = 5.81, P,0.05). Post-hoc Dunnett’s tests revealed that
only the low 3 mg/kg, i.p. dose caused a significant increase in
activity for BD1063 (q = 2.73, P,0.05), thereby indicating that the
alterations in locomotor behavior did not account for the changes
observed in the forced swim tests.
The second s1 receptor antagonist BD1047 alone displayed no
significant effects in the forced swim test (F[3,36] = 2.55, n.s.). In
the locomotor studies, BD1047 produced an effect that signifi-
cantly differed from saline injections (F[3,34] = 6.99, P,0.001).
Post-hoc Dunnett’s tests revealed that only the low 3 mg/kg, i.p.
dose caused a significant increase in activity for BD1047 (q = 3.70,
P,0.01).
Effects of Sigma Receptor Antagonists in the Presence of
Dextromethorphan or Imipramine
Pretreatment of mice with behaviorally inactive (10 mg/kg)
doses of BD1063 or BD1047, two well-established and selective s1
receptor antagonists, attenuated the antidepressant-like effects of
dextromethorphan, but not imipramine (Figure 2). Pretreatment
with BD1063 (10 mg/kg) attenuated the antidepressant-like effects
of dextromethorphan (30 mg/kg) (Figure 2A). ANOVA confirmed
a significant difference between the various treatment groups in
the antagonism study for dextromethorphan in the forced swim
test (F[3,41] = 5.59, P,0.01). Post-hoc Tukey’s multiple comparison
tests revealed that the dextromethorphan alone treatment group
differed significantly from saline (q = 5.60, P,0.001), as well as the
BD1063 + Dextromethorphan group (Figure 2A; q = 4.21,
P,0.05). Pretreatment of mice with BD1063 (10 mg/kg) also
significantly decreased the locomotor stimulatory effect of dextro-
methorphan (30 mg/kg), with an overall significant difference
between treatment groups (F[3,39] = 10.03, P,0.0001). More-
over, post-hoc Tukey’s test confirmed that BD1063 treatment
blocked the ability of dextromethorphan to increase locomotor
activity (q = 6.62, P,0.001).
Pretreatment with the second s1 preferring antagonist BD1047
showed a trend toward the attenuation of the antidepressant-like
effects of dextromethorphan (30 mg/kg), with the results of
10 mg/kg pretreatment with BD1047 illustrated in Figure 2B.
The overall ANOVA was significant for the BD1047 pretreatment
study (F[5,64] = 5.65, P,0.0005). Pairwise comparisons using post-
hoc Tukey’s multiple comparison tests further confirmed that the
BD1047 (10 or 20 mg/kg) + Dextromethorphan groups did not
differ significantly from saline (q = 4.04 and 2.77, n.s.). However,
the differences in the effects of dextromethorphan in the absence
and presence of BD1047 (10 or 20 mg/kg) were not significant
(q = 2.52 and 3.07, n.s.), reflecting partial attenuation of the effects.
In the locomotor studies, BD1047 significantly decreased the
effects of dextromethorphan (F[5,61] = 6.59, P,0.0001), with post-
hoc Tukey’s tests confirming the ability of BD1047 (10 mg/kg) to
block the stimulant effect of dextromethorphan (30 mg/kg)
(q = 5.41, P,0.05).
In contrast to the attenuation of dextromethorphan-induced
effects in the forced swim test, pretreatment with BD1063 did not
prevent, although it non-significantly reduced, the antidepressant-
like effects of imipramine (20 mg/kg) (Figure 2C). Post-hoc Tukey’s
Dextromethorphan and Antidepressant-like Effects
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Figure 1. Antidepressant-like effects of imipramine and dextromethorphan in the forced swim test in mice. Imipramine (0–20 mg/kg,
i.p.) significantly decreased immobility time (A), but had no significant effects on locomotor activity (B). Dextromethorphan (0–30 mg/kg, i.p.)
significantly decreased immobility time (C), and significantly increased locomotor activity (D). However, there was no correlation between
dextromethorphan (30 mg/kg)-induced locomotor stimulatory effects and decreased immobility times (E). Data shown are expressed as mean 6
S.E.M. *P,0.05, **P,0.01, ***P,0.001, compared with the saline-treated group; one-way ANOVA followed by post-hoc Dunnett’s tests. Pearson’s r
correlation test for correlation analysis. IM, imipramine. DM, dextromethorphan.
doi:10.1371/journal.pone.0089985.g001
Dextromethorphan and Antidepressant-like Effects
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test confirmed that imipramine significantly reduced immobility
time compared to saline (q = 6.74, P,0.001). Post-hoc comparisons
of the BD1063 + Imipramine group showed that its effects did not
differ significantly from imipramine alone (q = 2.00, n.s.), and there
was a significant reduction in immobility time compared to saline
(q = 4.55, P,0.05). Locomotor activity differed among the
treatment groups (F[3,39] = 5.49, P,0.01). Although imipramine
and BD1063 at the doses tested did not differ from saline (q = 1.01
and 0.13, respectively, n.s.), the combination of BD1063 +
Imipramine produced a significant decrease in locomotor activity
(q = 5.17, P,0.01).
Effects of Sigma Antagonist BD1063 on
Dextromethorphan Dose Response
When testing a single dose of BD1063 (10 mg/kg) against
different doses of dextromethorphan, the presence of BD1063
elicited a shift to the right in the dextromethorphan dose response
curve (Figure 3A). However, the animals exhibited abnormal
behaviors, particularly vocalization, during the locomotor tests
beginning at the 50 mg/kg dose of dextromethorphan in
combination with BD1063. Higher doses of dextromethorphan
were lethal, which limited the extent to which the dose response
could be characterized. In locomotor studies, when testing the
single dose of BD1063 (10 mg/kg) against increasing doses of
dextromethorphan, BD1063 appeared to block the dextromethor-
phan-induced locomotor activity (Figure 3B). However, as
mentioned above, the testing of higher doses of dextromethorphan
was not carried out due to behavioral toxicity.
Effects of CYP2D6 Inhibitor Quinidine on
Dextromethorphan Dose Response
Concurrent administration of quinidine (30 mg/kg), which
blocks the CYP2D6 metabolism of dextromethorphan [12],
potentiated the antidepressant-like effect of dextromethorphan
(10 mg/kg) (Figure 4A). ANOVA confirmed a significant differ-
ence between the various treatment groups (F[7,77] = 8.45,
Figure 2. Attenuation of the antidepressant-like effects of dextromethorphan, but not imipramine, by s1 receptor antagonism.
Pretreatment with the s1 receptor antagonist BD1063 (10 mg/kg, i.p.) prevented the dextromethorphan (30 mg/kg, i.p.)-induced decrease in
immobility time (A). BD1047 (10 mg/kg, i.p.) pretreatment also produced a noticeable, albeit not statistically significant, trend toward the prevention
of the decreased immobility time induced by dextromethorphan (B). In contrast, the antidepressant-like effect of imipramine (20 mg/kg, i.p.) in the
forced swim test was not significantly prevented by BD1063 pretreatment (C). Data shown are expressed as mean 6 S.E.M. *P,0.05, ***P,0.001,
compared with the saline-treated group; #P,0.05, compared with the dextromethorphan-treated group; one-way ANOVA followed by post-hoc
Tukey’s tests. IM, imipramine. DM, dextromethorphan.
doi:10.1371/journal.pone.0089985.g002
Dextromethorphan and Antidepressant-like Effects
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P,0.0001). Post-hoc Tukey’s multiple comparison tests revealed
that the dextromethorphan (30 mg/kg) treatment group differed
significantly from saline alone in the absence of quinidine
(q = 6.96, P,0.001) and in combination with quinidine (q = 7.11,
P,0.001). Importantly, while dextromethorphan at 10 mg/kg
alone was not significantly different from saline (q = 3.19, n.s.), it
produced a significant decrease in immobility time when
combined with quinidine (q = 6.78, P,0.001). In locomotor
studies, dextromethorphan in combination with quinidine had
no stimulant effects (Figure 4B). The overall ANOVA was
significant for the various treatment groups (F[7,73] = 3.97,
P,0.001). Pairwise comparisons using post-hoc Tukey’s multiple
comparison tests further confirmed that the dextromethorphan
(30 mg/kg) alone treatment group differed significantly from
saline (q = 6.40, P,0.001). In combination with quinidine,
however, dextromethorphan had no significant stimulant effects
(q = 4.04, n.s.). When tested alone, quinidine had no significant
effects in the forced swim test (t = 0.47, n.s.) nor did it have any
effect on locomotor activity (t = 0.99, n.s.).
Dextromethorphan Binding to Sigma-1 Receptors
The results of the s1 receptor saturation binding assays
demonstrated there was a significant reduction in Kd and Bmax
when the assays were performed in the presence of dextrome-
thorphan, compared to when no dextromethorphan was added to
the assay (Table 1). Unpaired t-tests revealed a significant decrease
in both Kd (t = 3.87, P,0.05) and Bmax (t = 4.29, P,0.05) with the
inclusion of 400 nM dextromethorphan in the assays.
Discussion
This study is the first to show that dextromethorphan has
antidepressant-like effects in vivo, in addition to implicating s1
receptors as a mechanism contributing to its antidepressant
actions. Moreover, concomitant administration of the CYP2D6
reversible inhibitor quinidine potentiated the effects of dextrome-
thorphan in the forced swim test. This demonstrates that the
antidepressant-like effects of dextromethorphan do not require
conversion to the metabolite dextrorphan, and reveals dextrome-
thorphan itself has antidepressant efficacy.
The antidepressant-like effects of dextromethorphan appear to
involve s1 receptors. In the current study, two well-established s1
receptor antagonists (BD1063 and BD1047) reduced the antide-
pressant-like actions of dextromethorphan in vivo. They are
thought to act in a competitive manner since in the presence of
BD1063, the dose response curve for dextromethorphan was
shifted to the right. An involvement of s1 receptors in the
antidepressant-like effects of dextromethorphan is consistent with
earlier reports that selective s1 receptor agonists can on their own
reduce immobility time in the forced swim test [17,20,21,32] and
produce antidepressant-like effects in other animal models such as
the tail suspension test and olfactory bulbectomy [18,33]. Thus,
additional studies involving these and other animal models used in
depression research (e.g., sucrose preference test, novelty suppres-
sion) [3,29,30] will be needed in the future to further evaluate the
antidepressant potential of dextromethorphan and the involve-
ment of s1 receptors.
The ability of dextromethorphan to elicit antidepressant-like
actions through s1 receptors suggests future studies to evaluate
potential fast-acting therapeutic effects are also warranted. s1
Receptor agonists can enhance serotonergic neuronal firing in the
dorsal raphe nucleus after only two days vs. two weeks of
treatment that is typically required of conventional antidepressant
drugs [24,25]. In addition, the fast-acting antidepressant drug
ketamine has recently been shown to potentiate nerve growth
factor (NGF)-induced neurite outgrowth through a s1-dependent
mechanism [26], supporting the emerging importance of s1
receptors in modulating neuronal plasticity, which itself is a critical
element for conveying both rapid and delayed antidepressant
activity.
Earlier competition binding studies showed that dextromethor-
phan has significant affinity for s1 receptors (138–652 nM)
[13,27,28,34], and thus further characterization of the interaction
of dextromethorphan with s1 receptors was undertaken in the
current study. The saturation binding studies indicate that the
Figure 3. Competitive antagonism of the behavioral effects of
dextromethorphan by BD1063. A single dose of BD1063 (10 mg/
kg, i.p.) pretreatment shifted the dextromethorphan (0–50 mg/kg, i.p.)
dose response curve to the right in the forced swim test (A), and
blocked the dextromethorphan-induced stimulatory effect in the
locomotor study (B). Data shown are expressed as mean 6 S.E.M.
*P,0.05, **P,0.01 compared with the dextromethorphan (30 mg/kg,
i.p.)-treated group; one-way ANOVA followed by post-hoc Tukey’s tests.
DM, dextromethorphan.
doi:10.1371/journal.pone.0089985.g003
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interaction of dextromethorphan with s1 receptors is complex,
with both a change in Bmax and Kd in the binding of [
3H](+)-
pentazocine in the presence of dextromethorphan. The reduction
in the number of s1 receptors (Bmax) with which [
3H](+)-
pentazocine binds suggests non-competitive interactions of dex-
tromethorphan with s1 receptors. However, there is also a
decrease in Kd for [
3H](+)-pentazocine binding in the presence of
dextromethorphan, suggesting additional competitive interactions.
Together, the data support the presence of at least two distinct sites
or modes of interaction with which dextromethorphan binds to the
s1 receptor, one with which it has competitive interactions, and
another with which it has non-competitive interactions. This
interpretation would be consistent with other reports of multiple
regions for ligand interactions on the s1 receptor, some of which
have functional ramifications for agonist vs. antagonist activity
[35,36,37]. The affinity differences of dextromethorphan for its
Figure 4. Potentiation of the antidepressant-like effects of dextromethorphan by quinidine. A single dose of the CYP2D6 inhibitor
quinidine (30 mg/kg, i.p.) administered concomitantly with dextromethorphan (0–30 mg/kg, i.p.) significantly potentiated the decrease in immobility
time for dextromethorphan at 10 mg/kg (A). In contrast, in the locomotor study, dextromethorphan in combination with quinidine had no
stimulatory effects (B). Data shown are expressed as mean 6 S.E.M. ***P,0.001, compared with the saline-treated group; one-way ANOVA followed
by post-hoc Tukey’s tests. QND, quinidine. DM, dextromethorphan.
doi:10.1371/journal.pone.0089985.g004
Table 1. Binding parameters for s1 receptors in the absence
and presence of dextromethorphan.
Assay condition Kd (nM) Bmax (fmol/mg protein)
No additional compound 27.3862.23 356612
+ Dextromethorphan 400 nM 16.8161.58a 29069a
Saturation binding assays in brain homogenates for s1 receptors were
conducted using [3H](+)-pentazocine as the radioligand. The assays were
performed in the absence or presence of dextromethorphan (400 nM). The Kd
and Bmax were determined using nonlinear regression. Dextromethorphan
produced a significant decrease in Kd and Bmax. Data shown are expressed as
mean 6 S.E.M. aP,0.05, compared with [3H](+)-pentazocine alone; paired t-test.
doi:10.1371/journal.pone.0089985.t001
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two putative binding sites appear to be similar (,100-fold
difference) since competition binding assays of dextromethorphan
at s1 receptors are consistent with a one-site fit [27]. The
antidepressant-like effects of dextromethorphan are thought to be
mediated through the competitive binding site since i) there
appears to be a rightward shift in its dose response curve in the
forced swim test with no apparent change in maximal effect, and
ii) (+)-pentazocine, the s1 agonist used to label the receptor, has
previously also been reported to produce similar antidepressant-
like effects [10,17].
In addition to interacting with s1 receptors, dextromethorphan
has been reported to alter monoamine reuptake, particularly
serotonin and norepinephrine at Ki values of 23 and 240 nM,
respectively [38], which have implications for antidepressant
effects in humans. The significant affinity of dextromethorphan for
SERT (40 nM) [9] would be expected to contribute to antide-
pressant efficacy in humans, although it would not account for
potential fast-acting effects, nor reductions in immobility time
herein. Under the experimental parameters used in the current
study, the classical SSRI fluoxetine did not produce significant
reductions in immobility time in the forced swim test. This is
consistent with the reports of others that the forced swim test does
not reliably detect the antidepressant potential of SSRIs [39].
Thus, this mechanism, which is a known contributor to
antidepressant efficacy in humans, is unlikely to account for the
pattern of antidepressant-like effects observed with dextromethor-
phan herein. In contrast to its high affinity for SERT,
dextromethorphan binds much more weakly with NET (.1 mM)
[9], but its reported ability to modulate norepinephrine reuptake
[38] would be expected to contribute conventional antidepressant
effects under clinical conditions.
Compared to the ability of BD1063 pretreatment to signifi-
cantly block the antidepressant-like effects of dextromethorphan, it
failed to attenuate that of imipramine, which has an overlapping
binding profile with dextromethorphan: SERT (1.3–20 nM)
[40,41,42,43], and s1 receptors (343 nM) [44]. This indicates
that the s1 interaction may have a larger role in producing the
antidepressant-like effects of dextromethorphan than that of
imipramine. This is consistent with the wider range of protein
targets through which imipramine, but not dextromethorphan,
interacts, which include: serotonin 5-HT2, muscarinic, and
histamine H1 receptors [9,45,46,47,48,49].
Finally, dextromethorphan elicits stimulant actions which were
quantified herein as increases in locomotor activity. Two
observations are of note with regard to these actions. First, the
stimulant effects cannot account for the antidepressant-like actions
of dextromethorphan. Second, quinidine enhances the antide-
pressant-like effects of dextromethorphan without producing an
increase in locomotor activity. This suggests that addition of
quinidine to dextromethorphan can be used clinically to optimize
therapeutic antidepressant actions, without eliciting unwanted
stimulant effects.
In conclusion, the data presented here show for the first time
that dextromethorphan has antidepressant-like effects in an in vivo
model and provide evidence that this effect occurs at least in part
through a s1 receptor dependent mechanism. This is also the first
report of the manner in which dextromethorphan interacts at the
s1 receptor. Together with earlier studies and the potential of
increasing dextromethorphan bioavailiabity by using the FDA-
and EMA-approved dextromethorphan/quinidine formulation,
these data suggest dextromethorphan should be further explored
for translational potential as an antidepressant drug in clinical
trials, as it may offer rapid-acting relief of depressive symptoms
and the ability to resolve cases of treatment-resistant depression. In
addition, further studies to understand the molecular and cellular
mechanisms by which these effects occur are necessary and may
yield important information about how various receptors, trans-
porters and processes are involved in the ability of dextromethor-
phan to convey its antidepressant effects.
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